RESUMEN
Adeno-associated virus (AAV) vector-mediated gene therapy is currently evaluated as a potential treatment for Crigler-Najjar syndrome (CN) (NCT03466463). Pre-existing immunity to AAV is known to hinder gene transfer efficacy, restricting enrollment of seropositive subjects in ongoing clinical trials. We assessed the prevalence of anti-AAV serotype 8 (AAV8) neutralizing antibodies (NAbs) in subjects affected by CN and investigated the impact of low NAb titers (<1:5) on liver gene transfer efficacy in an in vivo passive immunization model. A total of 49 subjects with a confirmed molecular diagnosis of CN were included in an international multicenter study (NCT02302690). Pre-existing NAbs against AAV8 were detected in 30.6% (15/49) of screened patients and, in the majority of positive cases, cross-reactivity to AAV2 and AAV5 was detected. To investigate the impact of low NAbs on AAV vector-mediated liver transduction efficiency, adult wild-type C57BL/6 mice were passively immunized with pooled human donor-derived immunoglobulins to achieve titers of up to 1:3.16. After immunization, animals were injected with different AAV8 vector preparations. Hepatic vector gene copy number was unaffected by low anti-AAV8 NAb titers when column-purified AAV vector batches containing both full and empty capsids were used. In summary, although pre-existing anti-AAV8 immunity can be found in about a third of subjects affected by CN, low anti-AAV8 NAb titers are less likely to affect liver transduction efficiency when using AAV vector preparations manufactured to contain both full and empty capsids. These findings have implications for the design of liver gene transfer clinical trials and for the definition of inclusion criteria related to seropositivity of potential participants.
Asunto(s)
Anticuerpos Neutralizantes/biosíntesis , Anticuerpos Antivirales/biosíntesis , Síndrome de Crigler-Najjar/terapia , Dependovirus/genética , Terapia Genética/métodos , Glucuronosiltransferasa/genética , Adolescente , Adulto , Animales , Bilirrubina/inmunología , Bilirrubina/metabolismo , Cápside/inmunología , Cápside/metabolismo , Niño , Preescolar , Síndrome de Crigler-Najjar/genética , Síndrome de Crigler-Najjar/inmunología , Síndrome de Crigler-Najjar/patología , Dependovirus/inmunología , Antagonistas de Aminoácidos Excitadores/uso terapéutico , Femenino , Expresión Génica , Glucuronosiltransferasa/deficiencia , Glucuronosiltransferasa/inmunología , Células HEK293 , Humanos , Inmunidad Innata , Inmunización Pasiva , Hígado/inmunología , Hígado/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Fenobarbital/uso terapéutico , Fototerapia/métodos , Plásmidos/química , Plásmidos/metabolismo , TransfecciónRESUMEN
UDP-Glucuronosyltransferase (UGT) 2A3 belongs to a UGT superfamily of phase II drug-metabolizing enzymes that catalyzes the glucuronidation of many endobiotics and xenobiotics. Previous studies have demonstrated that UGT2A3 is expressed in the human liver, small intestine, and kidney at the mRNA level; however, its protein expression has not been determined. Evaluation of the protein expression of UGT2A3 would be useful to determine its role at the tissue level. In this study, we prepared a specific antibody against human UGT2A3 and evaluated the relative expression of UGT2A3 in the human liver, small intestine, and kidney. Western blot analysis indicated that this antibody is specific to UGT2A3 because it did not cross-react with other human UGT isoforms or rodent UGTs. UGT2A3 expression in the human small intestine was higher than that in the liver and kidney. Via treatment with endoglycosidase, it was clearly demonstrated that UGT2A3 was N-glycosylated. UGT2A3 protein levels were significantly correlated with UGT2A3 mRNA levels in a panel of 28 human liver samples (r = 0.64, p < 0.001). In conclusion, we successfully prepared a specific antibody against UGT2A3. This antibody would be useful to evaluate the physiological, pharmacological, and toxicological roles of UGT2A3 in human tissues.
Asunto(s)
Anticuerpos/inmunología , Glucuronosiltransferasa/inmunología , Reacciones Antígeno-Anticuerpo , Glucuronosiltransferasa/genética , Glucuronosiltransferasa/metabolismo , Humanos , Microsomas/inmunología , Microsomas/metabolismo , ARN Mensajero/genética , ARN Mensajero/inmunología , ARN Mensajero/metabolismo , Proteínas Recombinantes/genética , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/metabolismo , Células Tumorales CultivadasRESUMEN
UDP-Glucuronosyltransferases (UGTs) are major phase II drug-metabolizing enzymes. Each member of the UGT family exhibits a unique but occasionally overlapping substrate specificity and tissue-specific expression pattern. Earlier studies have reported that human UGT1A10 is expressed in the gastrointestinal tract at the mRNA level, but the evaluation at the protein level, especially tissue or cellular localization, has lagged behind because of the lack of a specific antibody. In this study, we prepared a monoclonal antibody to UGT1A10 to elucidate the tissue/cellular distribution and interindividual variability of UGT1A10 protein expression. Western blot analysis revealed that the prepared antibody does not cross-react with any other human UGTs. Using this specific antibody, we observed that UGT1A10 protein is expressed in the small intestine but not in the liver or kidney. Immunohistochemical analysis revealed the expression of UGT1A10 protein in epithelial cells of the crypts and villi of the duodenum. In the small intestine microsomes from six individuals, the UGT1A10 protein levels exhibited 16-fold variability. Dopamine 3- and 4-glucuronidation, which is mainly catalyzed by UGT1A10 and by other UGT isoforms marginally, exhibited 50- to 65-fold variability, and they were not correlated with the UGT1A10 protein levels. Interestingly, the enzymatic activities of recombinant UGT1A10 in insect cells that were normalized to the UGT1A10 protein level were markedly lower than those in pooled human small intestine microsomes. Thus, the UGT1A10 antibody we generated made it possible to investigate the tissue/cellular distribution and interindividual variability of UGT1A10 protein expression for understanding the pharmacological and toxicological role of UGT1A10.
Asunto(s)
Anticuerpos Monoclonales/química , Glucuronosiltransferasa/metabolismo , Intestinos/enzimología , Adulto , Anciano , Secuencia de Aminoácidos , Animales , Anticuerpos Monoclonales/inmunología , Especificidad de Anticuerpos , Células Epiteliales/citología , Células Epiteliales/enzimología , Femenino , Glucuronosiltransferasa/biosíntesis , Glucuronosiltransferasa/inmunología , Células HEK293 , Células Hep G2 , Humanos , Intestinos/citología , Células MCF-7 , Masculino , Ratones , Ratones Endogámicos C57BL , Persona de Mediana Edad , Ratas , Ratas Sprague-DawleyRESUMEN
In immunity and inflammation, T cells are often associated with stromal mesenchymal cells such as fibroblasts. Hyaluronan and proteins that associate with hyaluronan such as versican and tumor necrosis factor-inducible gene-6 (TSG-6) are extracellular matrix (ECM) components that promote leukocyte adhesion, accumulation, and activation. However, the factors responsible for producing this specialized ECM and its impact on inflammatory events are not well understood. In this study, we explored the role of T cells in stimulating lung fibroblasts to produce an ECM that impacts monocyte adhesion. We found that CD3/CD28-activated human CD4+ T cells when co-cultured with human lung fibroblasts stimulated the expression of mRNA for hyaluronan synthase 2 (HAS2) and decreased the expression of hyaluronidase 2 (HYAL2). This led to an increase in the deposition of hyaluronan that formed cable-like structures within the ECM. Co-culturing activated T cells with fibroblasts also led to increased expression and accumulation of TSG-6. Surprisingly, addition of activated CD4+ T cells to the fibroblasts reduced the expression of mRNA for versican, and increased the expression of enzymes that degrade versican, such as ADAMTS4 and ADAMTS9 (a disintegrin and metalloproteinase with a thrombospondin type-1 motif) leading to a decrease in versican in the ECM of the co-cultures. Furthermore, addition of human monocytes to these co-cultures resulted in elevated monocyte adhesion to the cable-like structures in the ECM when compared to controls. These results illustrate the importance of crosstalk between T cells and fibroblasts in promoting the generation of a matrix that is adhesive for monocytes. J. Cell. Biochem. 118: 2118-2130, 2017. © 2016 Wiley Periodicals, Inc.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Matriz Extracelular/inmunología , Fibroblastos/inmunología , Ácido Hialurónico/biosíntesis , Monocitos/inmunología , Versicanos/biosíntesis , Proteína ADAMTS4/genética , Proteína ADAMTS4/inmunología , Proteína ADAMTS9/genética , Proteína ADAMTS9/inmunología , Linfocitos T CD4-Positivos/citología , Adhesión Celular , Moléculas de Adhesión Celular/genética , Moléculas de Adhesión Celular/inmunología , Comunicación Celular , Técnicas de Cocultivo , Matriz Extracelular/metabolismo , Fibroblastos/citología , Proteínas Ligadas a GPI/genética , Proteínas Ligadas a GPI/inmunología , Regulación de la Expresión Génica , Glucuronosiltransferasa/genética , Glucuronosiltransferasa/inmunología , Humanos , Hialuronano Sintasas , Ácido Hialurónico/inmunología , Hialuronoglucosaminidasa/genética , Hialuronoglucosaminidasa/inmunología , Pulmón/citología , Pulmón/inmunología , Activación de Linfocitos , Monocitos/citología , Cultivo Primario de Células , Transducción de Señal , Versicanos/inmunologíaRESUMEN
Hyaluronan synthases (HAS) are unique plasma membrane glycosyltransferases secreting this glycosaminoglycan directly to the extracellular space. The three HAS isoenzymes (HAS1, HAS2, and HAS3) expressed in mammalian cells differ in their enzymatic properties and regulation by external stimuli, but clearly distinct functions have not been established. To overview the expression of different HAS isoenzymes during embryonic development and their subcellular localization, we immunostained mouse embryonic samples and cultured cells with HAS antibodies, correlating their distribution to hyaluronan staining. Their subcellular localization was further studied by GFP-HAS fusion proteins. Intense hyaluronan staining was observed throughout the development in the tissues of mesodermal origin, like heart and cartilages, but also for example during the maturation of kidneys and stratified epithelia. In general, staining for one or several HASs correlated with hyaluronan staining. The staining of HAS2 was most widespread, both spatially and temporally, correlating with hyaluronan staining especially in early mesenchymal tissues and heart. While epithelial cells were mostly negative for HASs, stratified epithelia became HAS positive during differentiation. All HAS isoenzymes showed cytoplasmic immunoreactivity, both in tissue sections and cultured cells, while plasma membrane staining was also detected, often in cellular extensions. HAS1 had brightest signal in Golgi, HAS3 in Golgi and microvillous protrusions, whereas most of the endogenous HAS2 immunoreactivity was localized in the ER. This differential pattern was also observed with transfected GFP-HASs. The large proportion of intracellular HASs suggests that HAS forms a reserve that is transported to the plasma membrane for rapid activation of hyaluronan synthesis.
Asunto(s)
Glucuronosiltransferasa/farmacocinética , Ácido Hialurónico/biosíntesis , Animales , Anticuerpos/inmunología , Diferenciación Celular , Línea Celular Tumoral , Membrana Celular/metabolismo , Glucuronosiltransferasa/inmunología , Aparato de Golgi/metabolismo , Proteínas Fluorescentes Verdes/genética , Humanos , Hialuronano Sintasas , Células MCF-7 , Ratones , Ratones Endogámicos C57BLRESUMEN
Persistent inflammation is a well-known determinant of progressive tissue fibrosis; however, the mechanisms underlying this process remain unclear. There is growing evidence indicating a role of the cytokine IL-1ß in profibrotic responses. We previously demonstrated that fibroblasts stimulated with IL-1ß increased their generation of the polysaccharide hyaluronan (HA) and increased their expression of the HA synthase enzyme (HAS-2). The aim of this study was to determine the significance of IL-1ß-induced changes in HA and HAS-2 generation. In this study, we found that stimulation of fibroblasts with IL-1ß results in the relocalization of HA associated with the cell to the outer cell membrane, where it forms HAS2- and CD44-dependent cell membrane protrusions. CD44 is concentrated within the membrane protrusions, where it co-localizes with the intracellular adhesion molecule 1. Furthermore, we have identified that these cell protrusions enhance IL-1ß-dependent fibroblast-monocyte binding through MAPK/ERK signaling. Although previous data have indicated the importance of the HA-binding protein TSG-6 in maintaining the transforming growth factor ß1-dependent HA coat, TSG-6 was not essential for the formation of the IL-1ß-dependent HA protrusions, thus identifying it as a key difference between IL-1ß- and transforming growth factor ß1-dependent HA matrices. In summary, these data suggest that IL-1ß-dependent HA generation plays a role in fibroblast immune activation, leading to sequestration of monocytes within inflamed tissue and providing a possible mechanism for perpetual inflammation.
Asunto(s)
Extensiones de la Superficie Celular/inmunología , Fibroblastos/inmunología , Receptores de Hialuranos/inmunología , Ácido Hialurónico/biosíntesis , Interleucina-1beta/inmunología , Monocitos/inmunología , Adhesión Celular/inmunología , Moléculas de Adhesión Celular/inmunología , Diferenciación Celular/inmunología , Membrana Celular/inmunología , Células Cultivadas , Fibroblastos/fisiología , Glucuronosiltransferasa/inmunología , Humanos , Hialuronano Sintasas , Molécula 1 de Adhesión Intercelular/metabolismo , Sistema de Señalización de MAP Quinasas/inmunología , Monocitos/fisiología , Miofibroblastos/inmunología , Factor de Crecimiento Transformador beta1/inmunologíaRESUMEN
Acute graft versus host disease (aGvHD) is a major cause of early morbidity post-haematopoietic stem cell transplantation with minor histocompatibility antigens being a contributing factor. One mHA encoded by the UDP glycosyltransferase 2 family polypeptide B17 (UGT2B17) gene has been shown to be immunogenic because of differential expression in the donor and recipient. We investigated the effects of a homozygous gene deletion of UGT2B17 on the severity of acute aGvHD post-HSCT in HLA-matched related donors. 115 donor and recipient HLA and UGT2B17 genotypes were determined using PCR-SSO and PCR-SSP, respectively. aGvHD grading was determined using routine criteria and dichotomized into either nonclinically significant (0-I) or clinically significant (II-IV). For all analyses, P-values of ≤ 0.05 were considered significant. The frequency of the gene deletion within the total cohort tested was 29.1%. A significant increase in aGvHD severity (grades II-IV) was seen in UGT2B17 recipients expressing the protein when transplanted with a UGT2B17 disparate donor (P = 0.011). We observed a significant association between UGT2B17 expressing recipients and UGT2B17 deficient donors with the severity of aGvHD. This study provides additional evidence that genomic variations may predispose to more severe aGvHD, but are not a mechanism for GvHD.
Asunto(s)
Eliminación de Gen , Glucuronosiltransferasa/genética , Glucuronosiltransferasa/inmunología , Enfermedad Injerto contra Huésped/genética , Enfermedad Injerto contra Huésped/inmunología , Trasplante de Células Madre Hematopoyéticas , Adolescente , Adulto , Anciano , Niño , Preescolar , Femenino , Genotipo , Antígeno HLA-A2/genética , Antígeno HLA-A2/inmunología , Humanos , Lactante , Masculino , Persona de Mediana Edad , Antígenos de Histocompatibilidad Menor/genética , Oligopéptidos/genética , Adulto JovenRESUMEN
We investigated the role of the extracellular matrix component, hyaluronic acid (HA) in SEB-induced ALI/ARDS. Intranasal exposure of mice to SEB led to a significant increase in the level of soluble hyaluronic acid in the lungs. Similarly, in an endothelial cell/spleen cell co-culture, SEB exposure led to significant increases in soluble levels of hyaluronic acid, cellular proliferation, and cytokine production compared with SEB-exposed spleen cells or endothelial cells alone. Exposure of SEB-activated spleen cells to hyaluronic acid led to increased cellular proliferation and increased cytokine production. SEB-induced cytokine production and proliferation in vitro were significantly reduced by the hyaluronic acid blocking peptide, Pep-1. Finally, treatment of SEB-exposed mice with Pep-1 significantly reduced SEB-induced ALI/ARDS, through reduction of cytokine production and numbers of lung inflammatory cells, compared to mice treated with a control peptide. Together, these results suggest the possibility of targeting HA for the treatment of SEB-induced ALI/ARDS.
Asunto(s)
Enterotoxinas/inmunología , Ácido Hialurónico/inmunología , Pulmón/inmunología , Neumonía/inmunología , Enfermedad Aguda , Animales , Líquido del Lavado Bronquioalveolar/química , Líquido del Lavado Bronquioalveolar/inmunología , Línea Celular , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Técnicas de Cocultivo , Citocinas/genética , Citocinas/inmunología , Citocinas/metabolismo , Células Endoteliales/efectos de los fármacos , Células Endoteliales/inmunología , Células Endoteliales/metabolismo , Enterotoxinas/toxicidad , Ensayo de Inmunoadsorción Enzimática , Femenino , Citometría de Flujo , Glucuronosiltransferasa/genética , Glucuronosiltransferasa/inmunología , Glucuronosiltransferasa/metabolismo , Hialuronano Sintasas , Ácido Hialurónico/metabolismo , Hialuronoglucosaminidasa/genética , Hialuronoglucosaminidasa/inmunología , Hialuronoglucosaminidasa/metabolismo , Mediadores de Inflamación/inmunología , Mediadores de Inflamación/metabolismo , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Ratones , Ratones Endogámicos C57BL , Péptidos/farmacología , Neumonía/inducido químicamente , Neumonía/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Bazo/citología , Bazo/inmunología , Bazo/metabolismoAsunto(s)
Síndrome de Crigler-Najjar/terapia , Terapia Genética/métodos , Vectores Genéticos , Glucuronosiltransferasa/genética , Lentivirus/genética , Hígado/enzimología , MicroARNs/metabolismo , Animales , Anticuerpos/sangre , Células Presentadoras de Antígenos/inmunología , Bilirrubina/sangre , Biomarcadores/sangre , Síndrome de Crigler-Najjar/enzimología , Síndrome de Crigler-Najjar/genética , Síndrome de Crigler-Najjar/inmunología , Modelos Animales de Enfermedad , Glucuronosiltransferasa/biosíntesis , Glucuronosiltransferasa/inmunología , Humanos , Estabilidad del ARN , ARN Mensajero/metabolismo , Ratas , Ratas GunnRESUMEN
BACKGROUND & AIMS: Crigler-Najjar type 1 (CN-I) is an inherited liver disease caused by an absence of bilirubin-uridine 5'-diphosphate-glucuronosyltransferase (UGT1A1) activity. It results in life-threatening levels of unconjugated bilirubin, and therapeutic options are limited. We used adult Gunn rats (an animal model of the disease) to evaluate the efficiency of lentiviral-based gene therapy to express UGT1A1 in liver. METHODS: Gunn rats were given intraportal injections of VSVG-pseudotyped lentiviral vectors that encode UGT1A1 under the control of a liver-specific transthyretin promoter (mTTR.hUGT1A1); this vector does not contain target sequences for miR-142, a microRNA that is expressed specifically in hematopoietic cells. Rats were also injected with the vector mTTR.hUGT1A1.142T, which contains 4 copies of the miR-142 target sequences; its messenger RNA should be degraded in antigen-presenting cells. Bilirubinemia was monitored, and the presence of transduced hepatocytes was analyzed by quantitative polymerase chain reaction. Vector expression was tested in vitro in rat hematopoietic cells. RESULTS: In Gunn rats, bilirubin levels normalized 2 weeks after administration of mTTR.hUGT1A1. However, hyperbilirubinemia resumed 8 weeks after vector administration, concomitant with the induction of an immune response. In contrast, in rats injected with mTTR-UGT1A1.142T, bilirubin levels normalized for up to 6 months and transduced cells were not eliminated. CONCLUSIONS: Lentiviral vectors that express UGT1A1 reduce hyperbilirubinemia in immunocompetent Gunn rats for at least 6 months. The immune response against virally expressed UGT1A1 can be circumvented by inclusion of miR-142 target sequences, which reduce vector expression in antigen-presenting cells. This lentiviral-based gene therapy approach might be developed to treat patients with CN-I.
Asunto(s)
Síndrome de Crigler-Najjar/terapia , Terapia Genética/métodos , Vectores Genéticos , Glucuronosiltransferasa/genética , Lentivirus/genética , Hígado/enzimología , MicroARNs/metabolismo , Animales , Anticuerpos/sangre , Células Presentadoras de Antígenos/inmunología , Bilirrubina/sangre , Biomarcadores/sangre , Síndrome de Crigler-Najjar/enzimología , Síndrome de Crigler-Najjar/genética , Síndrome de Crigler-Najjar/inmunología , Modelos Animales de Enfermedad , Glucuronosiltransferasa/biosíntesis , Glucuronosiltransferasa/inmunología , Células HeLa , Humanos , Masculino , Prealbúmina/genética , Regiones Promotoras Genéticas , Estabilidad del ARN , ARN Mensajero/metabolismo , Ratas , Ratas Gunn , Factores de Tiempo , Transducción GenéticaRESUMEN
BACKGROUND: T-cell responses to minor histocompatibility antigens are mediators of graft-versus-host disease and organ graft rejection. We previously identified a human minor histocompatibility antigen that is recognized by CD8 cytotoxic T lymphocytes (CTLs) and encoded by the UDP glycosyltransferase 2 family, polypeptide B17 (UGT2B17) gene, which is highly expressed in the liver, colon, and small intestine. The UGT2B17 is presented by human leukocyte antigen (HLA)-A*2902, and the immunogenicity of this minor histocompatibility antigen results from differential protein expression in donor and recipient cells as a consequence of a UGT2B17 gene deletion. METHODS: An HLA-B*4403-restricted CD8 CTL clone was isolated from the same hematopoietic stem cell transplant recipient that exhibited an HLA-A*2902-restricted UGT2B17-specific response. The minor histocompatibility antigen recognized by the HLA-B*4403-restricted clone was identified, and the ability of the peptide to be presented by HLA-B*4402 was examined. RESULTS: The HLA-B*4403-restricted CTL clone recognized a peptide encoded by UGT2B17, which is identical to the peptide presented by HLA-A*2902. Peptide binding assays revealed this UGT2B17 peptide binds with comparable affinity to HLA-B*4402 as to HLA-B*4403. This patient had acute graft-versus-host disease involving liver and gastrointestinal tract, suggesting the T-cell response directed against UGT2B17 is involved in graft-versus-host disease. CONCLUSIONS: A single peptide encoded by UGT2B17 can be presented by HLA-A*2902, B*4402 and B*4403, and may serve as an immunodominant minor histocompatibility antigen in individuals with these HLA alleles that undergo transplantation of stem cells or organ grafts from UGT2B17 disparate donors.
Asunto(s)
Glucuronosiltransferasa/inmunología , Enfermedad Injerto contra Huésped/inmunología , Antígenos HLA-A/inmunología , Antígenos HLA-B/inmunología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Antígenos de Histocompatibilidad/inmunología , Antígenos de Histocompatibilidad Menor/inmunología , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Células COS , Células Cultivadas , Chlorocebus aethiops , Células Clonales , Epítopos/genética , Enfermedades Gastrointestinales/inmunología , Glucuronosiltransferasa/química , Antígeno HLA-B44 , Humanos , Hepatopatías/inmunología , Datos de Secuencia Molecular , Fragmentos de Péptidos/genética , Fragmentos de Péptidos/inmunología , Linfocitos T Citotóxicos/inmunologíaRESUMEN
Sera from AIH (autoimmune hepatitis) type 2 patients contain an autoantibody against the UGT1A subtype, called anti-LKM3. Previously, we reported that sera in AIH type 1 patients contained autoantibodies against drug-metabolizing enzymes (Shinoda et al. (2004) Autoimmunity, 37, 473). In this report, we showed that AIH-1 sera did not react with some peptides in the C-terminal half of the UGT1A subtype but reacted with a peptide P1(33-42) among several common peptides in the N-terminal half of the UGT1A subtype. This result suggests that the P1 site (33-42) presents on the outside of the UGT1A molecule to be recognized by lymphocytes of the immune system to produce an autoantibody. To detect a key recognition site on peptide P1(33-42), we studied the reactivity of two peptides, M1(28-37) and M2(38-47), containing the N-terminal and C-terminal half of peptide P1. Peptide M2 did not react with AIH-1 serum but peptide M1 did. Thus, the common peptide sequence 33-37 in the positive peptide M1(28-37) and P1(33-42) is a key recognition sequence. Next, we studied the reactivity of some other synthetic peptides, in which some amino acids in the sequence 33-37 in peptide M1 changed to Ala. The peptides changing to Ala (PQ33-34AA) or (DGS35-37AAA) did not react with AIH-1 sera. Meanwhile, these AIH sera did not inhibit the glucuronidation of p-nitrophenol by UGT1A6, suggesting that the key sequence 33-37 might not be contained in active sites of glucuronidation by UGT1A6. In conclusion, sera from AIH-1 patients reacted with the amino acids in the sequence 33-37 (PQDGS) of the N-terminal of UGT1A6.
Asunto(s)
Autoanticuerpos/inmunología , Glucuronosiltransferasa/inmunología , Hepatitis Autoinmune/inmunología , Secuencia de Aminoácidos , Ensayo de Inmunoadsorción Enzimática , Femenino , Glucurónidos/metabolismo , Humanos , Linfocitos/inmunología , Persona de Mediana Edad , Nitrofenoles/metabolismo , Péptidos/químicaRESUMEN
Crigler-Najjar (CN) patients have no bilirubin UDP glucuronosyltransferase (UGT1A1) activity and suffer brain damage because of bilirubin toxicity. Vectors based on adeno-associated virus (AAV) serotype 2 transduce liver cells with relatively low efficiency. Recently, AAV serotypes 1, 6, and 8 have been shown to be more efficient for liver cell transduction. We compared AAV serotypes 1, 2, 6, and 8 for correction of UGT1A1 deficiency in the Gunn rat model of CN disease. Adult Gunn rats were injected with CMV-UGT1A1 AAV vectors. Serum bilirubin was decreased over the first year by 64% for AAV1, 16% for AAV2, 25% for AAV6, and 35% for AAV8. Antibodies to UGT1A1 were detected after injection of all AAV serotypes. An AAV1 UGT1A1 vector with the liver-specific albumin promoter corrected serum bilirubin levels but did not induce UGT1A1 antibodies. Two years after injection of AAV vectors all animals had large lipid deposits in the liver. These lipid deposits were not seen in age-matched control animals. AAV1 vectors are promising candidates for CN gene therapy because they can mediate a reduction in serum bilirubin levels in Gunn rats that would be therapeutic in humans.
Asunto(s)
Síndrome de Crigler-Najjar/terapia , Dependovirus/genética , Terapia Genética/métodos , Vectores Genéticos/farmacología , Glucuronosiltransferasa/deficiencia , Animales , Bilis/fisiología , Bilirrubina/sangre , Síndrome de Crigler-Najjar/genética , Dependovirus/clasificación , Dependovirus/inmunología , Modelos Animales de Enfermedad , Técnicas de Transferencia de Gen , Vectores Genéticos/genética , Vectores Genéticos/inmunología , Glucuronosiltransferasa/genética , Glucuronosiltransferasa/inmunología , Hígado/efectos de los fármacos , Hígado/patología , Reacción en Cadena de la Polimerasa/métodos , Ratas , Ratas Gunn , Serotipificación , Distribución TisularRESUMEN
Expression of UDP-glucuronosyltransferases (UGT) in mammals is thought to be regulated in both a tissue- and developmental-specific manner. Furthermore, induction of genes encoding UGT occurs after exposure to xenobiotics including drugs, environmental pollutants and dietary compounds. In human, isoforms of UGT 1A subfamily catalyze the glucuronidation of a greater proportion of drugs, suggesting that the expression of UGT1A isoforms is responsible for the clearance of a diverse range of drugs. To analyze the expression of human UGT1A isoforms, we have developed polyclonal antibodies against specific peptide regions within the isoforms (UGT1A1, 1A3, 1A4, 1A6 and 1A9). The prepared antipeptide antibodies were found to be highly monospecific for each UGT1A isoform and no cross-reactivity with UGT2B isoforms was detected. Analysis of UGT1A protein levels in hepatic microsomes using these antibodies demonstrated interindividual differential expression of each isoform. These highly specific antipeptide antibodies provide an important tool to analyze tissue distribution and interindividual expression levels of human UGT1As.
Asunto(s)
Anticuerpos/inmunología , Glucuronosiltransferasa/inmunología , Hígado/enzimología , Péptidos/inmunología , Secuencia de Aminoácidos , Especificidad de Anticuerpos , Reacciones Cruzadas , Humanos , Isoenzimas/inmunología , Hígado/inmunología , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/enzimología , Datos de Secuencia Molecular , Distribución TisularRESUMEN
We have previously reported a mouse model of severe group A streptococcal infection (Microbiol. Immunol. 45: 777-786, 2001). When we injected Streptococcus pyogenes strains intramuscularly, the mice suffered from acute phase of infection for a few days but recovered from the illness and gained body weight. These mice, however, began to die after 3 weeks of infection, which we called 'delayed death.' Bacterial strains isolated from organs of the dead mice showed thick capsules. We, therefore, constructed a hyaluronic acid capsule gene, hasA, knockout mutant by homologous recombination and the effect of capsule on the death was observed. hasA knockout strain did not cause delayed death, though it caused acute death at high doses of infection. According to this result, the capsule is a critical pathogenic factor for causing the delayed death in our mouse model.
Asunto(s)
Cápsulas Bacterianas/inmunología , Glucuronosiltransferasa/deficiencia , Choque Séptico/microbiología , Infecciones Estreptocócicas/inmunología , Streptococcus pyogenes/inmunología , Animales , Cápsulas Bacterianas/genética , Glucuronosiltransferasa/genética , Glucuronosiltransferasa/inmunología , Humanos , Hialuronano Sintasas , Masculino , Ratones , Ratones Noqueados , Mutagénesis Insercional , Choque Séptico/inmunología , Estadísticas no Paramétricas , Infecciones Estreptocócicas/microbiología , Streptococcus pyogenes/enzimología , Streptococcus pyogenes/genéticaRESUMEN
Gene therapy for inherited disorders might cause an immune response to the therapeutic protein. A solution would be to introduce the gene in the fetal or neonatal period, which should lead to tolerization. Lentiviral vectors mediate long-term gene expression, and are well suited for gene therapy early in development. A model for fetal or neonatal gene therapy is the inherited disorder of bilirubin metabolism, Crigler-Najjar disease (CN). The absence of bilirubin UDP-glucoronyltransferase (UGT1A1) activity in CN patients causes high serum levels of unconjugated bilirubin and brain damage in infancy. CN is attractive for the development of gene therapy because the mutant Gunn rat closely mimics the human disease. Injection of UGT1A1 lentiviral vectors corrected the hyperbilirubinemia for more than a year in rats injected as fetuses and for up to 18 weeks in rats injected the day of birth. UGT1A1 gene transfer was confirmed by the presence of bilirubin glucuronides in bile. All animals injected with UGT1A1 lentiviral vectors developed antibodies to UGT1A1. Animals injected with green fluorescent protein (GFP) lentiviral vectors did not develop antibodies to GFP. Our results indicate that fetal and neonatal gene therapy with immunogenic proteins such as UGT1A1 does not necessarily lead to tolerization.
Asunto(s)
Síndrome de Crigler-Najjar/inmunología , Síndrome de Crigler-Najjar/terapia , Terapia Genética/métodos , Vectores Genéticos/administración & dosificación , Glucuronosiltransferasa/genética , Lentivirus/genética , Animales , Animales Recién Nacidos , Anticuerpos/sangre , Síndrome de Crigler-Najjar/embriología , Feto , Vectores Genéticos/genética , Glucuronosiltransferasa/inmunología , Proteínas Fluorescentes Verdes/genética , Proteínas Fluorescentes Verdes/inmunología , Tolerancia Inmunológica , Inyecciones , Hígado , Ratas , Ratas Gunn , Transducción Genética/métodosRESUMEN
We recently identified a human minor histocompatibility (H) antigen, encoded by UDP glycosyltransferase 2 family, polypeptide B17 (UGT2B17), whose immunogenicity results from differential expression in donor and recipient cells as a consequence of a homozygous deletion of the UGT2B17 gene. UGT2B17 is highly expressed in the liver and colon, which are major targets for graft-versus-host disease (GVHD). To assess the significance of homozygous UGT2B17 gene deletion in allogeneic haematopoietic stem cell transplantation (HSCT), we analysed DNA from 435 stem cell transplant recipients with a haematological malignancy and their human leucocyte antigen-identical unrelated bone marrow donors using sequence-specific primer polymerase chain reaction. Homozygous deletion of the UGT2B17 gene was observed in 85% of normal donors and in 82% of patients. The analysis showed no significant association between UGT2B17 mismatch in the GVHD direction and the incidence of acute GVHD, chronic GVHD, relapse, or survival. However, the use of a UGT2B17-positive donor was an independent risk factor for higher transplant-related mortality and lower survival after transplantation. UGT2B17 is a metabolic enzyme for hormones, drugs, and potentially toxic exogenous compounds and is expressed in subsets of haematopoietic cells. Thus, the enzyme function of UGT2B17 in donor cells may affect the outcome of allogeneic HSCT.
Asunto(s)
Eliminación de Gen , Glucuronosiltransferasa/genética , Enfermedad Injerto contra Huésped/genética , Neoplasias Hematológicas/cirugía , Trasplante de Células Madre , Enfermedad Aguda , Adolescente , Adulto , Factores de Edad , Distribución de Chi-Cuadrado , Niño , Preescolar , Enfermedad Crónica , Colon , Supervivencia sin Enfermedad , Femenino , Glucuronosiltransferasa/inmunología , Enfermedad Injerto contra Huésped/inmunología , Enfermedad Injerto contra Huésped/mortalidad , Neoplasias Hematológicas/inmunología , Neoplasias Hematológicas/mortalidad , Homocigoto , Humanos , Lactante , Recién Nacido , Hígado , Masculino , Persona de Mediana Edad , Antígenos de Histocompatibilidad Menor , Factores de Riesgo , Trasplante de Células Madre/mortalidad , Tasa de Supervivencia , Donantes de Tejidos , Inmunología del Trasplante , Trasplante HomólogoRESUMEN
Autoimmune hepatitis type 1 (AIH-1) is characterized by the detection of smooth muscle autoantibodies, antinuclear antibodies and antineutrophil cytoplasmic autoantibodies, and AIH-2 is characterized by the presence of autoantibodies against LKM, which contain drug-metabolizing enzymes. In this study, we measured the levels of drug-metabolizing enzymes in AIH-1 patients (ANA-positive). We exhaustively investigated the level of autoantibodies against major CYPs and UDP-glucuronosyltransferases of typical phase II drug-metabolizing enzymes, a transporter (MDR1), and NADPH-cytochrome P450 reductase in 4 patients with AIH-1 and 6 controls, as a case report. Two (Patients 3 and 4) of the AIH patients exhibited high levels of autoantibodies, while two (Patients 1 and 2) of the patients and the controls did not. The levels of autoantibodies against CYP2C19, CYP2D6, CYP2E1, UGT1A6 and human liver microsomes in Patients 3 and 4 sera were over 2(3) times the levels in Patient 1, Patient 2 and the control sera. Meanwhile, the levels of autoantibodies against CYP1A2, CYP2A6, CYP2C9, UGT2B7, MDR1 and NADPH-cytochrome P450 reductase were 2-2(2) higher in Patients 3 and 4 than in the other subjects. We found that the pattern of elevation in the Patient 3 serum was not parallel with that in Patient 4. Thus, we found high levels of autoantibodies against drug-metabolizing enzymes in AIH-1 patients.
Asunto(s)
Autoanticuerpos/sangre , Autoantígenos/inmunología , Hepatitis Autoinmune/inmunología , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/inmunología , Adulto , Hidrocarburo de Aril Hidroxilasas/inmunología , Citocromo P-450 CYP2A6 , Citocromo P-450 CYP2C9 , Sistema Enzimático del Citocromo P-450/inmunología , Ensayo de Inmunoadsorción Enzimática , Femenino , Glucuronosiltransferasa/inmunología , Humanos , Masculino , Microsomas Hepáticos/inmunología , Persona de Mediana Edad , Oxigenasas de Función Mixta/inmunologíaRESUMEN
Cytochromes P450 (CYP, phase I) and conjugating (phase II) enzymes can be induced by and influence the toxicokinetics (metabolism) and toxicity of xenobiotic contaminants in exposed organisms. Beluga whale (Delphinapterus leucas) from the endangered St. Lawrence (SL) River Estuary population exhibit deleterious health effects and various severe pathologies that have been associated with contaminant exposure. In contrast, such effects (e.g. reproductive and immunological impairment) are generally less frequent in less exposed populations in the Canadian Arctic (CA). In the present study, opportunistic sampling resulted in the collection immediately after death of liver tissue from a single female neonate SL beluga (SL6) and male and female CA beluga (n=10) from the Arviat region of western Hudson Bay, in addition to sampling of stranded carcasses of male and female SL beluga (n=5) at least 12 h postmortem. We immunologically characterized cross-reactive proteins of hepatic microsomal CYP1A, CYP2B, CYP3A, CYP2E, epoxide hydrolase (EH) and uridine diphosphoglucuronosyl transferase (UDPGT) isozymes. Cross-reactive proteins were found in all SL and CA beluga using anti-rat CYP1A1, anti-rainbow trout CYP3A, anti-human CYP2E1, anti-rabbit EH and anti-human UDPGT1A1 polyclonal antibodies (Abs), whereas faintly cross-reactive CYP2B proteins were only found in SL6 and the CA samples using an anti-rabbit CYP2B1 Ab. In corresponding catalytic activity assessments, only SL6 and all CA beluga microsomal samples exhibited CYP1A-mediated 7-ethoxyresorufin O-deethylase (EROD) activity (51-260 pmol/mg/min), CYP3A-mediated activity (113-899 pmol/mg/min) based on the formation of 6beta-hydroxytestosterone using a testosterone hydroxylase assay, and UDPGT activity (830-4956 pmol/mg/min) based on 1-naphthylglucuronide formation. The marginal cross-reactivity with the anti-CYP2B1 Ab and lack of catalytically measurable hydroxytestosterone isomers associated with CYP2B-type activity in all the SL and CA animals is suggestive of low CYP2B-type enzyme expression in beluga. The absence of measurable total P450 enzyme levels and catalytic activities in samples from the stranded SL belugas suggested catalytically inactive enzymes as a consequence of tissue degradation related due to the time delay of sample collection after death. However, all SL and CA animals demonstrated similar, immunologically cross-reactive phase I and II hepatic enzyme profiles, which is suggestive of the importance of metabolism in the toxicokinetics and fate of xenobiotics in animals from both populations
Asunto(s)
Anticuerpos/inmunología , Citocromo P-450 CYP1A1/metabolismo , Epóxido Hidrolasas/metabolismo , Glucuronosiltransferasa/metabolismo , Ballenas/inmunología , Ballenas/metabolismo , Animales , Regiones Árticas , Canadá , Cromatografía Líquida de Alta Presión , Reacciones Cruzadas , Citocromo P-450 CYP1A1/inmunología , Epóxido Hidrolasas/inmunología , Glucuronosiltransferasa/inmunología , Hidroxitestosteronas/metabolismo , Isoenzimas/inmunología , Isoenzimas/metabolismo , Microsomas Hepáticos/enzimología , Agua de Mar , EspectrofotometríaRESUMEN
Liver-Kidney Microsomes Type 3 (LKM3) autoantibodies (aAbs) have been described in chronic hepatitis D virus infection in 1983. The detection of such aAbs in autoimmune hepatitis (AIH) Type 2 was thereafter reported. The molecular targets of LKM3 aAbs have been identified as enzymes belonging to the UDP-glucuronosyltransferase family 1. Since 20-30% of suspected AIH are negative for the classical autoimmune serological markers, such as aAbs directed against antinuclear autoantibodies, smooth muscle autoantibodies and Liver-Kidney Microsomes Type 1 aAbs, LKM3 aAbs could be of great interest in the diagnosis of such negative AIH. In this review, we discuss the sensitivity and specificity of these aAbs in AIH in order to stress out their potential clinical use as a marker.